3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action Studies

Molecules. 2015 Aug 12;20(8):14595-610. doi: 10.3390/molecules200814595.

Abstract

The current pharmacological Chagas disease treatments, using Nifurtimox or Benznidazole, show limited therapeutic results and are associated with potential side effects, like mutagenicity. Using random screening we have identified new chemotypes that were able to inhibit relevant targets of the Trypanosoma cruzi. We found 3H-[1,2]dithioles with the ability to inhibit Trypanosoma cruzi triosephosphate isomerase (TcTIM). Herein, we studied the structural modifications of this chemotype to analyze the influence of volume, lipophilicity and electronic properties in the anti-T. cruzi activity. Their selectivity to parasites vs. mammalian cells was also examined. To get insights into a possible mechanism of action, the inhibition of the enzymatic activity of TcTIM and cruzipain, using the isolated enzymes, and the inhibition of membrane sterol biosynthesis and excreted metabolites, using the whole parasite, were achieved. We found that this structural framework is interesting for the generation of innovative drugs for the treatment of Chagas disease.

Keywords: 1H-NMR metabolomics; 3H-1,2-dithiole; anti-T. cruzi activity; cruzipain; membrane sterol biosynthesis; triosephosphate isomerase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Macrophages / drug effects
  • Mice
  • Sterols / antagonists & inhibitors
  • Sterols / biosynthesis
  • Toluene / analogs & derivatives*
  • Toluene / chemical synthesis
  • Toluene / chemistry
  • Toluene / pharmacology
  • Trypanocidal Agents / chemical synthesis
  • Trypanocidal Agents / chemistry*
  • Trypanocidal Agents / pharmacology*
  • Trypanosoma cruzi / drug effects*
  • Trypanosoma cruzi / metabolism

Substances

  • Sterols
  • Trypanocidal Agents
  • Toluene
  • dithiol